VYLOY (zolbetuximab) with Chemotherapy, Now Available for First-Line Treatment of Eligible Adult patients with Gastric and GEJ Adenocarcinoma in IndiaVMPLMumbai (Maharashtra) [India], July 30: Astellas Pharma India today announced that VYLOY (zolbetuximab) in combination with chemotherapy is now available for the first-line treatment of adult patients with gastric or gastroesophageal junction adenocarcinoma whose tumors are HER2 negative and CLDN18.2 positive in India. The SPOTLIGHT study evaluated VYLOY plus mFOLFOX6 (a combination chemotherapy regimen that includes oxaliplatin, leucovorin, and fluorouracil) compared to placebo plus mFOLFOX6. The GLOW study evaluated VYLOY plus CAPOX (a combination chemotherapy regimen that includes capecitabine and oxaliplatin) compared to placebo plus CAPOX. Both trials met their primary endpoint, progression-free survival (PFS), as well as a key secondary endpoint, overall survival (OS), in patients treated with VYLOY plus chemotherapy compared to placebo plus chemotherapy. VYLOY™ (zolbetuximab) is a prescription-only medicine approved by the Central Drugs Standard Control Organization (CDSCO), India, and must only be prescribed and administered by qualified medical professionals.